NYSE · PFE
Pfizer, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PFE: Nov 03, 2026
Pfizer, Inc. Common Stock is expected to report earnings on 11/03/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $0.72. The reported EPS for the same quarter last year was $0.87.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.72 | $0.80 | $0.67 | 5 |
| Dec 2026 | $0.71 | $0.76 | $0.64 | 4 |
| Mar 2027 | $0.85 | $0.85 | $0.85 | 1 |
| Jun 2027 | $0.70 | $0.70 | $0.70 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · RTTNews · Zacks- The Motley Fool · 4 h agoPfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?Pfizer shares are up amid bullish sentiment about the pharmaceutical company's turnaround efforts.
- RTTNews · Oct 30, 12:56 PM EDTWeekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals(RTTNews) – The biotech sector stayed active this week, with a mix of regulatory approvals, strategic partnerships, M&A activity, and clinical trial developments.
- Zacks · Oct 30, 8:36 AM EDTHALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
- Zacks · Oct 29, 11:23 AM EDTGSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
- Zacks · Oct 29, 10:58 AM EDTBMY Q3 Earnings Tops Estimates, Higher Charges Weigh on OutlookBristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
- Zacks · Oct 29, 9:22 AM EDTRecursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.
- Zacks · Oct 29, 8:15 AM EDTExploring Analyst Estimates for Pfizer (PFE) Q3 Earnings, Beyond Revenue and EPSGet a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
- Zacks · Oct 29, 6:45 AM EDTMerck (MRK) Surpasses Q3 Earnings and Revenue EstimatesMerck (MRK) delivered earnings and revenue surprises of +17.45% and +4.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 28, 4:45 PM EDTPfizer (PFE) Stock Sinks As Market Gains: Here's WhyPfizer (PFE) closed at $29.45 in the latest trading session, marking a -1.17% move from the prior day.
- Zacks · Oct 28, 10:26 AM EDTPfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.
- Zacks · Oct 28, 10:20 AM EDTAmgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.
- Zacks · Oct 28, 7:55 AM EDTHow to Boost Your Portfolio with Top Medical Stocks Set to Beat EarningsInvestors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Pfizer, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.